In a Phase II clinical trial of progressive metastatic carcinoma with or without MMR deficiency, whole-exome sequencing revealed a significantly increased somatic mutations per tumor (mean, 1782 vs. 73) in MMR–deficient tumors as compared with MMR–proficient tumors. This evidence concerns the gene MRC1 and metastatic carcinoma.